Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, gives an overview of bispecific antibodies emerging in multiple myeloma, drawing focus on BCMA-targeting agents including teclistamab and elranatamab, GPRC5D-targeting agents including talquetamab, and FcRH5-targeting agents including cevostamab. Dr Voorhees comments on the promising results obtained with these agents in clinical trials, as well as the side effects associated with the use of bispecifics. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.